// App-Quantinova.ai

PO‐093 : Duration of therapy is independently associated with improved progression free and overall survival following first line therapy in non‐transplant eligible patients with multiple myeloma: real‐life experience from a UK centre

Researchers

Presenter

  • D De-Silva

Principal Investigators

  • A Bloomfield

  • N Counsell

  • S Cheesman

  • J Galinsky

  • S Richard

  • A Rismani

  • N Rabin

  • S D'Sa

  • C Kyriacou

  • A Mehta

  • R Popat

  • K Yong

Medical Centers

  • Haematology Department, University College London Hospitals, London, UK

  • Newcastle University, Newcastle Upon Tyne, UK

  • Cancer Research UK, London

  • Myeloma UK, Edinburgh, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Bortezomib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved